Deal of the Week: Houston oncology co. to merge with struggling pharma co. in Boston

Olivia Pulsinelli
Deal of the Week: Houston oncology co. to merge with struggling pharma co. in Boston

Houston-based Salarius Pharmaceuticals LLC, a clinical-stage oncology company, will merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS). The combined company will be named Salarius Pharmaceuticals Inc. and will focus on developing Salarius’ drugs. The deal is expected to close in the first half of 2019, with Flex Pharma stockholders and current Salarius investors owning approximately 19.9 percent and 80.1 percent of the combined company, respectively.